Ag2R la Mondiale Gestion D'Actifs 13F: Adds $3.4M to LLY Stake
Key Points
- Ag2R la Mondiale Gestion D'Actifs increased its Eli Lilly stake by 2,948 shares, bringing its total to 38,166 shares worth about $44.2 million.
- The stock closed at $1,279.14 on October 26, 2026, and recently traded around $1,279.16, showing stability in its price.
- Eli Lilly has a market cap of approximately $1.14 trillion and a P/E ratio of 42.75, reflecting strong growth potential in the healthcare sector.
Get Eli Lilly and Company text alerts
We text you when insiders, Congress, analysts or big funds move on $LLY.
By entering your mobile number and tapping the sign-up button, you provide express written consent to receive recurring automated text messages from TradeTexts at that number, including stock alerts about SEC filings, insider and congress trades, analyst ratings, hedge fund moves, and earnings results. Consent is not a condition of any purchase. Message frequency varies. Messages are not investment advice. Message and data rates may apply. Reply HELP for help and STOP to opt out at any time. See our Terms and Privacy Policy.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Eli Lilly and Company alert may contain errors. Disclosures
On October 26, 2026, Ag2R la Mondiale Gestion D'Actifs boosted its stake in Eli Lilly and Company (LLY) by 2,948 shares, increasing its total to 38,166 shares valued at approximately $44.2 million. This information comes from the fund's latest Form 13F filing with the SEC.
Ag2R la Mondiale Gestion D'Actifs's increase in shares represents an 8.37% change. The fund now holds about 2.91% of its total reported 13F value in Eli Lilly, ranking it 9th among its 425 positions.
LLY
Eli Lilly and Company
Where Eli Lilly Fits in Ag2R la Mondiale Gestion D'Actifs's Portfolio
Eli Lilly now makes up 2.91% of Ag2R la Mondiale's portfolio, increasing its position by 2,948 shares.
Eli Lilly and Company Stock Up 0.4%
Eli Lilly's stock closed at $1,279.14 on October 26, 2026, and recently traded around $1,279.16, which is about equal to its closing price. The stock is currently above its 50-day moving average by 7.8% and its 200-day moving average by 17.9%.
Recent Earnings
Eli Lilly reported trailing twelve-month revenue of about $79.67 billion, with an EPS of $29.79. The next earnings report is scheduled for October 29, 2026.
Dividend
Eli Lilly pays an annual dividend rate of $6.92, resulting in a yield of 0.54%.
Insider Buying and Selling at Eli Lilly and Company
Several insiders sold shares recently. General Counsel Anat Hakim sold 5,000 shares on August 7, 2026, at an average price of $1,190, totaling about $5.95 million. Officer Donald A Zakrowski sold 2,000 shares on August 10, 2026, for about $2.37 million, while Officer Patrik Jonsson sold 6,500 shares on August 17, 2026, valued at approximately $7.64 million.
Analysts Set New Price Targets
On September 28, 2026, JP Morgan maintained an Overweight rating with a price target of $1,500. Morgan Stanley also maintained an Overweight rating on October 7, 2026, with a target of $1,430. The consensus among analysts is a "buy" recommendation, with a mean target price of $1,331.55 from 30 analysts.
About Eli Lilly
Eli Lilly and Company is a major player in the healthcare sector, focusing on discovering, developing, manufacturing, and marketing pharmaceutical products internationally. The recent boost in Ag2R la Mondiale's stake highlights continued interest in the company amid its strong market performance.
Bottom Line
Investors will be watching Eli Lilly closely as it prepares for its next earnings report on October 29, 2026. Ag2R la Mondiale's recent increase in stake shows confidence in the company's future prospects.
Related Filing Alerts
Source: Ag2R la Mondiale Gestion D'Actifs's 13F filing on $LLY (Oct 26, 2026). 13F filings show holdings as of the end of the reporting quarter and may not reflect the fund's current position. Written by software, not financial advice. How we make alerts